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Introduction

I

n the rapidly evolving arena of HIV prevention clinical trials, informed consent is recognized as a critical dimension of making ethics operational. While
ensuring informed consent and voluntary participation is one of the most complicated aspects of any clinical trial, HIV prevention trials, many of which are
being conducted in resource-poor settings, pose even greater ethical and practical challenges:
• Large-scale efficacy trials need to be conducted in areas with a high incidence
of HIV.
• Trials require healthy volunteers, who often are economically and socially vulnerable and at substantial risk of HIV infection.
• Researchers must reinforce the unknown efficacy of test products so that participants do not feel a false sense of protection, or “therapeutic misconception,” which could lead to increased risk behaviors (reducing condom use or
increasing numbers of partners).
• HIV/AIDS prevention trials involve highly sensitive issues: stigma, sexuality,
and gender-based power dynamics.
• Conveying technical research terms and unfamiliar concepts in local languages
can be difficult.
These challenges are exacerbated in settings of low literacy, where potential
research participants may have little understanding of sexual health or clinical
research.

To address these challenges, the Population Council and Family Health
International (FHI) convened a meeting to identify successful approaches to the
informed consent process that could be adapted and shared widely among
researchers implementing HIV prevention trials. This brief, adapted from the
full meeting report,1 focuses on innovative tools and strategies being used to
facilitate informed consent in HIV prevention trials, and incorporates illustrative
examples from completed and ongoing trials.

1

C. Elizabeth McGrory, Barbara A. Friedland, Cynthia Woodsong, and Kathleen M. MacQueen.
2006. Informed Consent in HIV Prevention Trials: Report of an International Workshop. New York:
Population Council and Family Health International. Available at: www.popcouncil.org/pdfs/
ICWorkshop.pdf.
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Informed consent tools:
Communicating difficult concepts

I

nvestigators in a number of current HIV prevention studies are investing in a
range of creative tools and approaches to improve study volunteers’ understanding of research concepts and trial procedures, including study booklets, fact
sheets, flip charts, videos, visual aids, and interactive computer-based participant
education.2

Tips for developing informed consent
materials and approaches
• Conduct careful formative research: draft, pretest, and adapt to local
settings.
• Engage study staff, community advisory board members, potential
participants, and, if possible, participants from earlier studies in generating ideas, developing approaches, and pretesting materials.
• Draw on community advisory boards and other community structures to reinforce key concepts, such as voluntarism, and to assist
with developing language, terms, and analogies that convey research
concepts that are relevant and understandable in the local setting.
• Use materials in combination to build on and reinforce each other in
presenting relevant information to the community and participants
throughout the clinical trial process.

2

Interactive technologies can include ACASI— audio computer-assisted self-“instruction” or self-“interview”—
either used to provide information to study volunteers or as an interview technique for eliciting
responses on sensitive topics.

3
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Booklets

A

well-produced booklet conveys a trial's professionalism and respect for participants. Lifelike color illustrations may help participants understand and
retain information. Study booklets can be beneficial for:
• providing general or detailed information to research participants about the
study steps and procedures, and for supplementing informed consent forms;
• defining and illustrating complex research concepts graphically;
• responding to questions during information sessions;
• helping with recruitment if participants show booklets to friends or relatives.
Informed consent tools in practice: Population Council Phase 3 Carraguard® trial
The Population Council's Carraguard® Phase 3 microbicide trial3 booklet supplemented the informed consent form. During pre-testing, participants voiced opinions about the images, color, and overall quality of the booklet, leading to design
changes (see box).
Informed consent tools in practice: HPTN 035 microbicide trial
The booklet for the HIV Prevention Trials Network's (HPTN) 035 microbicide
trial4 uses line drawings of a character named Serena to explain many of the
study's concepts and procedures. This multisite trial was conducted in several
countries, so materials were pilot tested and adapted to each setting. Although
Serena was intentionally designed to look familiar to the population of women
being recruited for the trial, pretesting resulted in Serena being redrawn to
appear more modern, attractive, and affluent. Further, one drawing of Serena
was interpreted by many potential participants as appearing worried and was
subsequently redrawn (see box).

3
A Phase 3 safety and efficacy trial of the microbicide Carraguard to prevent HIV seroconversion
in women was conducted at three sites in South Africa between March 2004 and March 2007.
www.popcouncil.org/projects/MIC_CarraClinicalStudies3.html. Accessed 17 January 2008.
4

The HPTN 035 trial is a four-arm randomized Phase 2/2b safety and effectiveness trial of two candidate
microbicides and two control arms that enrolled 3,220 women in eight sites in five countries.
www.hptn.org/research_studies/hptn035.asp; www.mtnstopshiv.org/node/62. Accessed 17 January 2008.
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Adaptation of Carraguard Phase 2 booklet for Phase 3
Phase 2

Phase 3

Study participants in the Phase 2 Carraguard trial recommended that illustrations for
the information booklet (left) be more realistic. Changes were made to the Carraguard
Phase 3 booklet (right).

Evolution of “Serena” for HPTN 035

In pretests, participants helped to develop Serena, used in the booklets for the trial.
(Artwork by Denise Todloski)

5
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Videos

V

ideos offer the potential of facilitating recruitment and informed consent
processes, particularly in large-scale trials. Videos can be more engaging
than print media, may be an especially useful tool in settings with low literacy,
and can help in standardizing provision of trial information and reducing the
burden on study staff.
Challenges for video technology include:
• The complex development process requires a long lead time, which can make
it difficult to accommodate protocol changes.
• Showing a video may not be feasible at all recruitment locations since bringing expensive equipment to local sites can be cumbersome or even dangerous.
• Attracting the attention of potential participants in busy clinics may be difficult.
Informed consent tools in practice: MIRA study of the latex diaphragm to
prevent HIV infection in women
MIRA trial5 staff found that participants tended to be bored by written materials or by hearing staff present information; volunteers indicated that a video
would help keep them engaged.
• Clinicians, community members, and the research team were involved in
developing the video.
• Trial participants responded positively to the appearance in the video of the
chair of the ethics committee, which:
–helped to give a real face to the concept of the “ethical review”;
–sent the message that participants are valued;
–conveyed the study's professionalism.

5

The MIRA (Methods for Improving Reproductive Health in Africa) trial is being conducted in Durban
and Johannesburg, South Africa, and Harare, Zimbabwe. www.cervicalbarriers.org/documents/
MIRA_Results_ and_Publications_aug07_final_pdf.pdf. Accessed 17 January 2008.

6
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Informed consent tools in practice: Population Council Phase 3 Carraguard trial
To inform approaches for the Phase 3 efficacy trial of Carraguard® in South
Africa, the Population Council conducted focus-group discussions and in-depth
interviews with Phase 2 trial participants and staff.6 The Council sought to identify ways to explain difficult concepts and solicited suggestions for the recruitment and informed consent processes for the Phase 3 trial. On the basis of the
responses, the Population Council developed a video7 to clarify unfamiliar concepts and to present basic information in a more engaging manner.
• Vignettes were used to convey difficult concepts and key themes such as randomization, double blinding, voluntary participation, partner communication, the pelvic exam (an unfamiliar procedure for most women in the trial
communities), and HIV testing.
• An educational consultant helped to develop the script, and a well-known
actress appeared as the on-camera narrator.
• Sections of the video were pretested and adapted following focus-group discussions with women in the trial communities and with community advisory
board members.
• Anecdotal reports suggest that study staff and trial participants found the
video informative and interesting; women appreciated seeing in advance what
they would experience in the trial.

6
A. De Kock, M. Marumo, and B. Friedland. 2005. “Carraguard Phase 3 Trial: Developing and implementing a video.” Presentation at the Population Council/Family Health International Workshop on
Informed Consent in HIV Prevention Trials, New York, 16-18 May.
7

“Testing Carraguard™. What you Need to Know.” Video. Johannesburg: Population Council, 2004.
Produced by Pandamonium Productions. www.popcouncil.org/media/saclips/videolink.html. Accessed
17 January 2008.

7
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Interactive computer-based participant education
Informed consent tools in practice: BOTUSA Project PrEP trial
The BOTUSA Project PrEP trial8 presented a plan for using interactive computerassisted self-instruction as reinforcement after an intensive face-to-face consenting
process and prior to administration of a comprehension test. The technology
employs a touch-screen computer with an audio component, and information
about the trial is communicated in a multimedia presentation with an accompanying narration; participants have the option of selecting a language.

8

The Botswana PrEP Trial, a study to evaluate the safety and efficacy of pre-exposure prophylaxis in
reducing HIV infection among heterosexual young adults, is being conducted by the BOTUSA Project—
a collaboration of the Botswana Government and the U.S. Centers for Disease Control and Prevention
(CDC). www.cdc.gov/hiv/resources/factsheets/prep.htm. Accessed 17 January 2008.

8
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Explaining difficult concepts

C

linical trial concepts and research terms are particularly difficult to convey
to study volunteers in diverse settings and languages in a way that ensures
understanding. Trial staff are employing innovative approaches to present information and explain complex concepts in educational and informed consent
materials used in local settings.9, 10

Examples of innovative ways for explaining difficult concepts discussed at
the meeting include:
Randomization: A procedure for dividing participants into treatment groups by
random allocation, used to eliminate selection bias by researchers or participants,
ensure that statistical analysis of data will be valid, and create groups compatible
with respect to factors that could influence outcome. Randomization is a complex research concept that may be unfamiliar to potential participants and is difficult to explain consistently in diverse settings:
• Randomization is often explained by using images associated with the notion
of chance, such as a lottery machine or rolling dice (see box).
• An image of a computer can make the point that a computer program, rather
than a person, randomly assigns a trial participant to the intervention or control group.
Randomization

Images of objects associated with the idea of chance—rolling dice—were used to explain
that participants are selected randomly for a study’s intervention and control groups.
Left, illustration from the Carraguard Phase 3 trial; right, from the BOTUSA PrEP trial.
9

H. Bracken. 2005. “Communicating complex concepts.” Presentation at the Population Council/Family
Health International Workshop on Informed Consent in HIV Prevention Trials, New York, 16–18 May.

10

Because the effectiveness of these methods for conveying information to trial participants has not
been systematically evaluated, they should be considered suggestions rather than “best practice.”

9
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Placebo: Explanations emphasize that the study product and the placebo are
identical except that the placebo:
• Is “inactive,” or “doesn't have [name of active ingredient] in it”
• “One contains [the active ingredient] and one does not”
• Is a “comparison gel” (see box)
Other ways to explain placebos include analogous images that should be
drawn from and tested in the local context to ensure that the example is relevant:
• Vitamin-enriched juice or milk
• Costume jewelry versus real gemstones
• Imitation colas versus Coke™
Serodiscordance: It can be particularly difficult to convey the concept that one
partner can be HIV positive and the other HIV negative. To encourage couples
to be tested for HIV, the Partners in Prevention HSV/HIV trial11 uses an analogy of baobab trees infected with termites (see box). One cannot tell from afar
which tree has termites nor which partner has HIV without testing. The baobab
tree analogy will be appropriate in some settings but not relevant in others, illustrating the importance of pretesting and adapting images and language in each
setting to ensure that they convey relevant messages and facilitate understanding.
Sensitive issues: Sexuality and other sensitive issues are addressed through either
explicit or suggestive images (see boxes):
• Some materials use drawings such as shoes or clothes by a bed (without
depicting people) to suggest sexual activity.
• Others use a more explicit drawing of a nude man and woman lying together.
• Similarly, the pelvic exam can be depicted in explicit or less graphic images.
• One trial includes the pelvic exam illustration only in materials used at the
clinic site but not in materials that participants take home, to address the concern that explicit depictions in printed materials could be seen by other people and may stigmatize the study or the participants.

11

A Phase 3 trial of acyclovir for HSV-2 suppression among HIV-discordant couples, being
conducted in multiple sites in Africa by the Partners in Prevention project (University of Washington).
http://clinicaltrials.gov/show/NCT00194519; http://depts.washington.edu/hsvhiv/public/index.html.
Accessed 17 January 2008.
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Placebo
Carraguard +
condoms

Page 11

Comparison gel +
condoms

The two baobab trees look similar
although one is infected with termites
that can destroy one or both of the
trees. The illustration is used as an
analogy for HIV, which can infect one or
both partners but cannot be diagnosed
without testing. Illustration from
Partners in Prevention HSV/HIV trial.

Animation in the Carraguard Phase 3
video emphasized that the product and
the placebo look the same and are used
in the same way.

Pelvic exam

Sexual activity

Some participants expressed concern that
being too explicit in materials that may be
taken home or seen by other people may
stigmatize the study or the participants. Top
picture from BOTUSA Project PrEP trial;
bottom from HTPN.

Depending on the study site, the materials in various Carraguard trials used
explicit images (top-South Africa) or
suggestive ones (bottom-Thailand) to
suggest sex.

11
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Assessing comprehension among trial
participants: What do participants need to know?

A

s part of improving informed consent, many trial staff are grappling with
how to measure participants' understanding of trial issues. Researchers
designing informed consent assessments confront a choice about whether to
employ quantitative approaches or qualitative approaches (see Appendix 1).
• Should comprehension of specific concepts and study procedures be considered essential, such that volunteers must demonstrate their understanding
before they are allowed to enroll?
• What methods should be used to assess comprehension?
Although a volunteer's full comprehension of all elements of a trial is the
aim of informed consent, achieving this level of understanding may not always
be possible. Many researchers considered a number of issues to be critical for trial
volunteers to understand:
• Purpose of the research.
• Experimental nature of the study.
• Uncertainty about the test product’s efficacy in preventing HIV infection.
• Need to continue other risk-reduction practices during participation in the
study.
• Concepts of randomization, blinding, and placebos.
• Study procedures, risks, benefits, voluntarism, and confidentiality.
See Appendix 2 for an example of HPTN's comprehension assessment tool.

12
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The importance of training

E

ven the best materials, tools, and assessments are of limited use if study staff
are not given the training and support to use them appropriately and consistently. Developing and employing approaches for conveying complex issues
and improving informed consent, and for evaluating their efficacy, can be costly
and requires the resources and commitment of the trial sponsors, donors, and
trial teams. Sufficient resources must be allocated in trial budgets for ongoing
training and evaluation.

Conclusion

R

esearchers and study staff across all settings should share strategies and tools
for maximizing and assessing participants' comprehension and improving
informed consent. In addition to building evidence for continued investment,
such exchanges also can contribute to resolving common challenges, from decisions about which media and strategies to use, to training, to specific approaches for conveying complex concepts.

13
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Appendix 1: Quantitative and qualitative approaches
Quantitative
Approaches
(closed-ended
questions, true/false,
multiple choice)

Qualitative
Approaches
(open-ended
questions)

Strengths

• Better for eliciting specific
information, one-word
answers, or for checking
facts
• Simple to administer
• Evaluation is relatively
objective
• Requires less staff training

• Encourages people to say
more, ask questions, and
reveal more clearly whether
information has been
understood
• Allows participant to
respond in his/her own
words in a dialogue consistent with the spirit of
informed consent
• Staff can get a sense of
whether a participant can
apply information to deciding whether to participate in
a trial and to follow the
protocol

14

Weaknesses

• Limited for assessing comprehension of complex concepts
• Can create illusion that participant
has understood, while only measuring short-term ability to repeat
information
• Choosing precise wording/terms
is complicated in multi-site
trials/multiple languages
• True/false and multiple choice
questions include incorrect statements that can confuse
volunteers
• True/false assessments tend to
be skewed to “true” statements
• True/false approach not familiar in
many settings; volunteers may
consider it impolite to say that a
statement a counselor has made
is “wrong”
• Evaluation is subjective; requires
more sophisticated and nuanced
judgment by staff of volunteer's
understanding
• Requires more extensive staff
training and ongoing support
• Requires greater staff time to
implement
• Enrollment targets may create
disincentive for staff to determine
that a volunteer does not understand the information well enough
to enroll
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Appendix 2: HPTN 035 trial: Enrollment informed
consent comprehension checklist, Version 1.0 (Excerpted)

The HPTN 035 trial uses an open-ended assessment of questions that reflect the required elements
of informed consent according to the US Code of Federal Regulations. Within each of these items
are more specific elements. These are “must knows” that volunteers are required to answer correctly
in order to be enrolled.
Open-Ended
Questions/Statement

Required Points of Comprehension

2. What do you understand
that you are being asked
to do in this study?

Asked to use condoms and perhaps gel with
each act of vaginal sex
Have pelvic exams and HIV tests
Come for monthly visits for up to 30 months
Not get pregnant in next 30 months

1. Please describe your
understanding of the
purpose of the study.

3. What do you understand
about possible risks that
might happen as a result
of being in the study?
4. What will happen to you
if you decide not to join
the study?
5. Please tell me about the
different groups of
women in the study.

Study is testing two experimental gels
Testing to know if gels are safe
Testing to learn if gels may prevent HIV
Study may not prove gels work

✓

Comments

Gel may irritate skin inside or outside vagina
Gel may have other side effects
Possibility of social harms
Free to make own decision about joining
No effect on access to care when decide to
join or not
There are different gels
Not everyone receives a gel
No one knows who receives which gel

Outcome:
■ Demonstrated comprehension of all required points, decided to enroll in study.
■ Demonstrated comprehension of all required points, decided NOT to enroll in study.
■ Demonstrated comprehension of all required points, deferred enrollment decision to
another visit.
■ Did not demonstrate comprehension of all required points (yet), needs more time/discussion,
rescheduled for another visit.
■ Unable to demonstrate comprehension of all required points, consent process discontinued.

Staff signature: ________________________________________________________________
Source: A.S. Coletti. 2005. “HPTN 035 informed consent comprehension assessment.” Presentation at the Population
Council/Family Health International Workshop on Informed Consent in HIV Prevention Trials, New York, 16-18 May.
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